Anti-Parkin Antibody, clone 2J8 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2JB is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects Parkin. It targets an epitope within 22 amino acids from the C-terminal half.

KLH-conjugated linear peptide corresponding to 22 amino acids from the C-terminal region of human Parkin.

Quality Control Testing

Evaluated by Immunohistochemistry (Paraffin) in human gallbladder tissue sections.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution of this antibody detected Parkin in human gallbladder tissue sections.

Tested applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Parkin in lysates from HeLa cells stably transfected with HA-Parkin and SH-SY5Y cells.

Affinity Binding Assay:: A representative lot of this antibody bound Parkin with a KD of 7.6 x 10-8 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Parkin in SH-SY5Y cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

E3 ubiquitin-protein ligase parkin (UniProt: O60260; also known as EC:2.3.2.31, Parkin, Parkin RBR E3 ubiquitin-protein ligase, Parkinson juvenile disease protein 2, Parkinson disease protein 2) is encoded by the PRKN (also known as PARK2) gene (Gene ID: 5071) in human. Parkin is mainly localized in the cytosol but relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential. Its mitochondrial recruitment is shown to be PINK1-dependent. Parkin functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto various substrate proteins. It mediates monoubiquitination as well as polyubiquitination of substrates. It participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating lysine 63-linked polyubiquitination of misfolded proteins. It is reported to offer protection against mitochondrial dysfunction during cellular stress, by acting downstream of PINK1 to coordinate mitochondrial quality control mechanisms that remove and replace dysfunctional mitochondrial components. Parkin is also reported to mediate monoubiquitination of Bcl2 and acts as a positive regulator of autophagy and promotes the autophagic degradation of dysfunctional depolarized mitochondria by promoting the ubiquitination of TOMM20, RHOT1/MIRO1 and USP30. In its autoinhibited state the side chain of phenylalanine 463 inserts into a hydrophobic groove in RING-0 that occludes the ubiquitin acceptor site Cys-431. Its activation is a two-step process that involves serine 65 phosphorylation by PINK1 and binding to phosphorylated ubiquitin that leads to unlock repression of the catalytic Cys-431 by the RING-0 region via an allosteric mechanism and converting PRKN to its fully active form. Mutations in PRKN gene are known to cause Parkinson disease characterized by bradykinesia, resting tremor, muscular rigidity, and postural instability. This ZooMAbZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Vives-Bauza, C., et al. (2010). Proc. Natl. Acad. Sci. USA. 107(1); 378-383; Shimura, H., et al. (2000). Nat. Genet. 25(3); 302-305; Imai, Y., et al. (2000). J. Biol. Chem. 275(46); 35661-35664).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.